@Simonwhite 1 month ago
Tough update from EyePoint Pharmaceuticals today
Tough update from EyePoint Pharmaceuticals today
it is really tough to watch that 69% drop for EyePoint Pharmaceuticals after the trial news. do you think has enough other projects to keep going or is this a total dealbreaker for investors?
@JacobFosterr 1 month ago
A 69% drop is brutal, but the bigger question is whether its pipeline can still create enough upside to offset this setback. Would you stay invested or move on?
@AntonioMyers 1 month ago
do you think eyepoint pharmaceuticals has enough cash to keep their other trials going after this?
